 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | ARTHSHAKTI FOUNDATION |
| Street 1: | AMANI STREET, KARIAKOO |
| Street 2: | |
| City: | DAR ES SALAAM |
| Province: | DAR ES SALAAM |
| Post Code: | |
| Country: | United Republic of Tanzania |
| Phone: | 0626542766 |
| Organization Email: | HELP@ARTHSHAKTIFOUNDATION.ORG |
| Web Site: | http://www.asftanzania.org |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 3495 |
| Organization Type - Primary: | Non-Governmental Organization |
| Organization Type - Secondary: | Other Non-Governmental Organization (NGO) |
| Organization Description: | |
| Arthshakti Foundation is an International NGO in Tanzania. Our main focus to reduce health cost for the people. Our mission to reach and teach to all Tanzanian to live economically, healthy and fit. We want partnership to reduce TB patient in Tanzania. TB control and planning involves a multi-pronged approach, including early detection, prompt treatment, infection control measures, and community engagement, guided by national strategic plans. Early identification of persons with active TB through entry and periodic follow-up screening. Successful treatment of active TB and latent TB infection. Appropriate use of airborne precautions (e.g., airborne infection isolation, environmental controls, and respiratory protection) Comprehensive discharge planning. |
|
| Do you know about the UNHLM declaration: | No |
Specializations / Areas of Work | |
|
Delivery of health services and care |
Other Organization Information | |
| Total number of staff in your organization: | 1 - 5 |
| Number of full-time staff who are directly involved with TB: | 0 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | No |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We will start survey, that how many people are in early age and other TB patient. We will do health camps in the effected Area and provide them medicines, educate to the people about decease. We will call doctors and specialist from outside of the country to give better treatment to the TB patient. | |
Geographical Reach | |
| Which country is your headquarters located in: | United Republic of Tanzania |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
United Republic of Tanzania |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: Advocacy: Engaging policymakers and stakeholders to prioritize TB control and allocate resources. Communication: Raising awareness about TB prevention, symptoms, and treatment options through targeted campaigns and educational materials. Social Mobilization: Involving communities, civil society, and health workers to support TB patients, reduce stigma, and encourage adherence to treatment. Drug-Resistant TB: Multidrug-Resistant TB (MDR-TB): Resistant to Isoniazid (INH) and Rifampicin (RIF), the two most powerful first-line drugs. Extensively Drug-Resistant TB (XDR-TB): Resistant to INH, RIF, any fluoroquinolone, and at least one second-line injectable drug (like amikacin or kanamycin). Pre-Extensively Drug-Resistant TB (Pre-XDR TB): Resistant to INH, RIF, and any fluoroquinolone but not to second-line injectables. Rifampicin-Resistant TB (RR-TB): Resistant to Rifampicin alone or with other drugs. TB-HIV: Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are closely linked. People living with HIV (PLHIV) are 20-30 times more likely to develop active TB due to their weakened immune system. Fundamental Research: TB Pathogenesis Understanding how TB bacteria infect the lungs and other organs. Drug Resistance Mechanisms Identifying genetic mutations that lead to Drug-Resistant TB (DR-TB). Host Immune Response Studying how the immune system responds to TB infection. TB Biomarkers Developing new diagnostic tools to detect TB infection. Vaccine Development Research on next-generation TB vaccines. Latent TB Infection (LTBI) Mechanism Understanding why some people develop active TB while others remain asymptomatic. |
|
Declaration | |
| Declaration of interests: I have no real, potential, or apparent conflict of interest with respect to the Global Partnership to Stop TB or any of its associated programs, projects, or initiatives. My role is to provide neutral, evidence-based information to support TB care delivery, research, and advocacy efforts. | |
| Application date: | March 13, 2025 |
| Last updated: | March 13, 2025 |